<DOC>
	<DOCNO>NCT02072928</DOCNO>
	<brief_summary>This study evaluate impact BOTOX® treatment anticholinergic drug use patient urinary incontinence Neurogenic Detrusor Overactivity ( NDO ) due spinal injury Multiple Sclerosis ( MS ) prescribe BOTOX® standard care clinical practice .</brief_summary>
	<brief_title>Study Botulinum Toxin Type A ( BOTOX® ) Treat Urinary Incontinence From Neurogenic Detrusor Overactivity Belgium</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients prescribe BOTOX® urine incontinence NDO due spinal injury MS standard care clinical practice Belgium Previous treatment anticholinergic drug ineffective Last BOTOX® treatment ≥18 month . Diagnosis urinary incontinence le 9 month . No anticholinergic drug use last 9 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>